Form 4: Castle Biosciences CEO Sells Over 22,000 Shares Under Pre-Arranged Trading Plan

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 22,576 shares of common stock for approximately $20.3 per share on June 27, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences Inc. (CSTL), reported the sale of 22,576 shares of common stock.
• The sales occurred on June 27, 2025, at a weighted-average price of $20.3 per share, with individual trades ranging from $20.00 to $20.51.
• These transactions were executed under a Rule 10b5-1 trading plan established on November 11, 2024.
• The shares were sold directly by Mr. Maetzold (4,944 shares) and indirectly through various trusts: The Maetzold Descendants 2020 Trust (8,068 shares), Derek Maetzold 2020 Irrevocable Trust (6,924 shares), and four Maetzold 2018 Remainder Trusts (660 shares each).
• Following these transactions, Mr. Maetzold directly holds 69,683 shares and indirectly holds 231,032 shares through various trusts, including those that did not participate in the reported sales (DJM Grantor Retained Annuity Trust No. 5 and No. 6).

Sentiment

Score: 5

Explanation: Neutral. While an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal typically associated with insider selling. It suggests planned diversification or liquidity rather than a reaction to adverse company news.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct equity stake, which can sometimes be perceived negatively by investors as it might signal a lack of confidence, although this is mitigated by the pre-planned nature.

Future Outlook

Not applicable. This document is an insider transaction report and does not contain forward-looking statements or guidance.

Industry Context

This document details a specific insider transaction for Castle Biosciences Inc. and does not provide broader industry context or trends.

Related Party Transactions

• Sales were conducted by Derek J. Maetzold directly and indirectly through several trusts where he or his spouse are trustees and/or beneficiaries, or where his children are beneficiaries. These include The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and four Maetzold 2018 Remainder Trusts.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some shareholders as a slight reduction in management's direct equity alignment, though the pre-planned nature lessens the impact.

Key Dates

Recommendation

Keywords

Castle Biosciences, CSTL, SEC Form 4, Insider Trading, Stock Sale, Derek J. Maetzold, Rule 10b5-1 Plan, Common Stock, Officer Transaction, Director Transaction